利妥昔单抗作为儿童自身免疫性溶血性贫血二线治疗的获益:一项法国前瞻性队列研究
这项法国前瞻性全国研究纳入2000至2014年间接受利妥昔单抗治疗的61例儿童自身免疫性溶血性贫血(AIHA)及Evans综合征(ES)患者。46例(75%)有应答,6年无复发生存率为48%,利妥昔单抗使44/61(72%)的儿童得以停用糖皮质激素。孤立性AIHA的完全缓解率和6年无复发生存率显著高于ES(P<0·05)。
要点
- 61例患儿中46例(75%)对利妥昔单抗有应答,6年无复发生存率为48%。
- 利妥昔单抗使44/61(72%)的患儿得以停用糖皮质激素。
- 孤立性AIHA的完全缓解率和6年无复发生存率显著高于ES(P<0·05)。
核心结论
- 这项大型儿童AIHA观察性系列研究确立了利妥昔单抗的获益-风险比,可使患儿停用糖皮质激素,37%为长期应答者,主要见于孤立性AIHA。
- 所有亚组患者均从利妥昔单抗治疗中获益。
- 作者的长期结果表明,这一基线结果需要新的治疗方法来挑战。
研究设计与样本
- 前瞻性全国性研究,报告2000年至2014年间接受利妥昔单抗治疗的61例儿童孤立性AIHA及Evans综合征(ES)患者的实践、疗效和耐受性。
主要发现
- 从诊断到使用利妥昔单抗的中位间隔为9·9个月(四分位距1·6-28·5个月)。
- 46例患者有应答(75%),6年无复发生存率为48%。
- 20例患者在中位间隔10·8个月(四分位距3·9-18·7个月)时复发。
- 利妥昔单抗使44/61(72%)的儿童得以停用糖皮质激素。
- 孤立性AIHA的完全缓解率和6年无复发生存率显著高于ES(P<0·05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Childhood autoimmune haemolytic anaemia (AIHA) requires second-line immunosuppressive therapy in 30-50% of cases. It appears that rituximab is indicated in such circumstances. This prospective national study reports the practice, efficacy and tolerance of rituximab in children with isolated AIHA and AIHA in the setting of Evans syndrome (ES). Sixty-one children were given rituximab between 2000 and 2014. The median interval from diagnosis to rituximab was 9·9 [interquartile range (IQR) 1·6-28·5] months. Forty-six patients responded (75%) and the 6-year relapse-free survival (RFS) was 48%. Twenty patients relapsed at a median interval of 10·8 (IQR 3·9-18·7) months, rituximab allowed steroid withdrawal in 44/61 (72%) of children. In isolated AIHA, complete response and 6-year RFS were significantly higher than in ES (P < 0·05). Ten out of 61 patients were infants, seven of who responded with a 6-year RFS of 71%. Among patients without immunoglobulin substitution before rituximab, 4 are still receiving substitutions. Five patients died, including one potentially attributable to rituximab. This large observational series of childhood AIHA established the rituximab benefit-risk ratio, allowing steroid withdrawal, with 37% of long-term responders, mainly in isolated AIHA. All subgroups of patients drew benefit. Our long-term results indicate the baseline to be challenged by new treatment approaches.
引用
- Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol. 2017. PMID: 28444729. doi:10.1111/bjh.14627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。